nach oben

Internal and Emergency Medicine

Erschienen in:

27.06.2019 | IM - COMMENTARY

Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

verfasst von: Francesco Violi, Daniele Pastori

Erschienen in: Internal and Emergency Medicine | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Excerpt

The INSIghT investigators performed a real-world prospective observational cohort study to investigate the safety and efficacy of non-vitamin K antagonist oral anticoagulants (NOACs) in 632 patients with atrial fibrillation (AF) according to the presence of chronic kidney disease (CKD), defined by a creatinine clearance (CrCl) < 60 ml/min [1]. Patients with CKD (n = 219) were at higher thromboembolic risk, as they were older, more likely to be women, hypertensive and diabetic. Among NOACs, apixaban was the most commonly used anticoagulant in CKD patients, followed by dabigatran and rivaroxaban. No patients on edoxaban were included. …

Godino C, Melillo F, Rubino F, Arrigoni L, Cappelletti A, Mazzone P, Mattiello P, Della Bella P, Colombo A, Salerno A, Cera M, Margonato A, Investigators IN (2019) Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease. Intern Emerg Med. https://doi.org/10.1007/s11739-019-02100-9 CrossRefPubMed

Hu WS, Lin CL (2019) Comparison of incidence of acute kidney injury, chronic kidney disease and end-stage renal disease between atrial fibrillation and atrial flutter: real-world evidences from a propensity score-matched national cohort analysis. Intern Emerg Med. https://doi.org/10.1007/s11739-019-02089-1 CrossRefPubMed

Violi F, Pastori D, Perticone F, Hiatt WR, Sciacqua A, Basili S, Proietti M, Corazza GR, Lip GY, Pignatelli P, Group AS (2015) Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. BMJ Open 5(5):e008026. https://doi.org/10.1136/bmjopen-2015-008026 CrossRefPubMedPubMedCentral

Apostolakis S, Guo Y, Lane DA, Buller H, Lip GY (2013) Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J 34(46):3572–3579. https://doi.org/10.1093/eurheartj/eht328 CrossRefPubMed

Posch F, Ay C, Stoger H, Kreutz R, Beyer-Westendorf J (2019) Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Res Pract Thromb Haemost 3(2):207–216. https://doi.org/10.1002/rth2.12189 CrossRefPubMedPubMedCentral

Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L (2015) Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 65(23):2481–2493. https://doi.org/10.1016/j.jacc.2015.03.577 CrossRef

Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR, Committee RAS, Investigators (2016) On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation 134(1):37–47. https://doi.org/10.1161/CIRCULATIONAHA.116.021890 CrossRefPubMed

Yao X, Tangri N, Gersh BJ, Sangaralingham LR, Shah ND, Nath KA, Noseworthy PA (2017) Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 70(21):2621–2632. https://doi.org/10.1016/j.jacc.2017.09.1087 CrossRefPubMed

Providencia R, Marijon E, Boveda S, Barra S, Narayanan K, Le Heuzey JY, Gersh BJ, Goncalves L (2014) Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol 114(4):646–653. https://doi.org/10.1016/j.amjcard.2014.05.048 CrossRefPubMed

10.

Prisco D, Ageno W, Becattini C, D'Angelo A, Davi G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F, SIMI, FADOI, SISET (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12(3):387–406. https://doi.org/10.1007/s11739-017-1628-6 CrossRefPubMed

11.

Miyazawa K, Pastori D, Lip GYH (2018) Changes in renal function in patients with atrial fibrillation: efficacy and safety of the non-vitamin K antagonist oral anticoagulants. Am Heart J 198:166–168. https://doi.org/10.1016/j.ahj.2017.11.015 CrossRefPubMed

12.

Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M (2016) Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 116(5):975–986. https://doi.org/10.1160/TH16-05-0403 CrossRefPubMed

13.

Norby FL, Bengtson LGS, Lutsey PL, Chen LY, MacLehose RF, Chamberlain AM, Rapson I, Alonso A (2017) Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 17(1):238. https://doi.org/10.1186/s12872-017-0672-5 CrossRefPubMedPubMedCentral

14.

Coleman CI, Kreutz R, Sood NA, Bunz TJ, Eriksson D, Meinecke AK, Baker WL (2019) Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. Am J Med. https://doi.org/10.1016/j.amjmed.2019.04.013 CrossRefPubMed

15.

Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, Kaewput W, Pachariyanon P, Cheungpasitporn W (2018) Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis. Pacing Clin Electrophysiol 41(6):627–634. https://doi.org/10.1111/pace.13331 CrossRefPubMed

16.

Gallagher AM, Rietbrock S, Plumb J, van Staa TP (2008) Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 6(9):1500–1506. https://doi.org/10.1111/j.1538-7836.2008.03059.x CrossRefPubMed

17.

O'Brien EC, Simon DN, Allen LA, Singer DE, Fonarow GC, Kowey PR, Thomas LE, Ezekowitz MD, Mahaffey KW, Chang P, Piccini JP, Peterson ED (2014) Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 168(4):487–494. https://doi.org/10.1016/j.ahj.2014.07.002 CrossRefPubMed

18.

Ferroni E, Gennaro N, Costa G, Fedeli U, Denas G, Pengo V, Corti MC (2019) Real-world persistence with direct oral anticoagulants (DOACs) in naive patients with non-valvular atrial fibrillation. Int J Cardiol 288:72–75. https://doi.org/10.1016/j.ijcard.2019.04.061 CrossRefPubMed

19.

Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, Valdes M, Vicente V, Lip GYH, Marin F (2017) Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost 117(7):1448–1454. https://doi.org/10.1160/TH16-12-0961 CrossRefPubMed

20.

Hohnloser SH, Basic E, Nabauer M (2019) Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study. Thromb Haemost 119(6):882–893. https://doi.org/10.1055/s-0039-1683428 CrossRefPubMed

21.

Volterrani M, Iellamo F, Alberto C, Pasquale A, Salvatore P, Massimo P, Marco M, Lucia U, Cesare P, Bruno R, Enrico P, Investigators S (2018) NOAC in "real world" patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. Intern Emerg Med 13(7):1069–1075. https://doi.org/10.1007/s11739-018-1896-9 CrossRefPubMed

Titel: Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
verfasst von: Francesco Violi
Daniele Pastori
Publikationsdatum: 27.06.2019
Verlag: Springer International Publishing
Erschienen in: Internal and Emergency Medicine / Ausgabe 8/2019
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-019-02135-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

A 29-year-old woman with persistent thrombocytopenia

Telemedicine and decentralized models of care: from anticoagulant monitoring to an expanded concept of vascular medicine

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting

Intentional foreign body ingestion

Focus on echocardiographic right ventricular strain analysis in cystic fibrosis adults without cardiovascular risk factors: a case–control study

Direct oral anticoagulants in factor VII deficiency patient

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin